Alteplase
| Clinical data | |
|---|---|
| Trade names | Activase, Actilyse |
| AHFS/Drugs.com | Monograph |
| License data | |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C2569H3928N746O781S40 |
| Molar mass | 59042.3 g/mol g·mol−1 |
| (verify) | |
Alteplase (trade names Activase, Actilyse) is a thrombolytic drug, used to treat acute myocardial infarctions (heart attacks) and other severe conditions caused by blood clotting by breaking up the blood clots that cause them.
It is a tissue plasminogen activator. It is approved by the US Food and Drug Administration for the treatment of myocardial infarction with ST-elevation (STEMI), acute ischemic stroke (AIS), acute massive pulmonary embolism, and occluded central venous access devices (CVAD).[1][2][3]
Medical uses
The primary uses of alteplase, as approved by the FDA, include acute ischemic stroke, acute myocardial infarction, and acute massive pulmonary embolism.[4]
References
- ^ "Thrombolytic Therapy: Background, Thrombolytic Agents, Thrombolytic Therapy for Acute Myocardial Infarction". 2017-05-02.
{{cite journal}}: Cite journal requires|journal=(help) - ^ Drugs.com: Monograph for Activase.
- ^ Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. 2017. Actilyse-Pulver und Lösungsmittel zur Herstellung einer Injektions- oder Infusionslösung. ISBN 3-85200-196-X.
- ^ Activase [package insert]. South San Francisco, CA: Genentech, Inc.; 2018.
 | This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it. |